globenewswire.com · 9 jun

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.

fool.com · 30 may

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

marketbeat.com · 9 may

Vericel Q1 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

seekingalpha.com · 7 may

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

zacks.com · 7 may

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

globenewswire.com · 7 may

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

zacks.com · 4 may

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

globenewswire.com · 23 abr

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.